The cytokines: The interferon family - Pharmaceutical Biotechnology: Concepts and Aapplications - page 240

Schooltink, H. and Rose, J. 2002. Cytokines as therapeutic drugs. Journal of Interferon and Cytokine Research
22 (5), 505-516.
Taniguchi, T. 1995. Cytokine signalling through non-receptor protein tyrosine kinases. Science 268 , 251-255.
Takatsu, K. 1997. Cytokines involved in B cell differentiation and their sites of action. Proceedings of the Society
for Experimental Biology and Medicine 215 (2), 121-133.
Yoshimura, A. 2005. Negative regulation of cytokine signalling. Clinical Reviews in Allergy and Immunology
28 (3), 205-220.
Interferons
Alberti, A. 1999. Interferon alfacon-1. A novel interferon for the treatment of chronic hepatitis C. Biodrugs 12 (5),
343-357.
Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N.D., and Zoon, K.C. 2004. Human interferons alpha, beta
and omega. Growth Factors 22 (4), 243-251.
Belardelli, F., Ferrantini M., Proietti E., and Kirkwood J.M. 2002. Interferon-alpha in tumor immunity and im-
munotherapy. Cytokine and Growth Factor Reviews 13 (2), 119-134.
Boehm, U., Klamp, T., Groot, M., and Howard, J.C. 1997. Cellular responses to interferon-gamma. Annual Re-
view of Immunology 15 , 749-795.
Brassard, D.L., Grace, M.J., and Bordens, R.W. 2002. Interferon-alpha as an immunotherapeutic protein. Journal
of Leukocyte Biology 71 (4), 565-581.
Cencic, A. and La Bonnardiere, C. 2002. Trophoblastic interferon-gamma: current knowledge and possible role
in early pig pregnancy. Veterinar y Research 33 (2), 139-157.
Chelmonska-Soyta, A. 2002. Interferon-tau and its immunological role in ruminant reproduction. Archivum Im-
munologiae et Therapiae Experimentalis 50 (1), 47-52.
Colonna, M., Krug, A., and Cella, M. 2002. Interferon-producing cells: on the front line in immune responses
against pathogens. Current Opinion in Immunology 14 (3), 373-379.
Foster, G. 2004. PEGylated interferons: chemical and clinical differences. Alimentary Pharmacology and Thera-
peutics 20 (8), 825-830.
Haria, M. and Benfi eld, P. 1995. Interferon-α-2a. Drugs 50 (5), 873-896.
Jonasch, E. and Haluska, F. 2001. Interferon in oncological practice: review of interferon biology, clinical ap-
plications and toxicities. Oncologist 6 (1), 34 -55.
Katre, N. 1993. The conjugation of proteins with polyethylene glycol and other polymers - altering properties of
proteins to enhance their therapeutic potential. Advanced Drug Delivery Reviews 10 (1), 91-114.
Kirkwood, J. 2002. Cancer immunotherapy: the interferon-alpha experience. Seminars in Oncology 29 (3), 18-
26.
Leaman, D.W., Leung, S., Li, X., and Stark, G.R. 1996. Regulation of stat-dependent pathways by growth factors
and cytokines. FASEB Journal 10 (14), 1578-1588.
Leon, M. and Zuckerman, S. 2005. Gamma interferon: a central mediator in atherosclerosis. Infl ammation Re-
search 54 (10), 395- 411.
Li, J. and Roberts, M. 1994. Interferon-τ and interferon-α interact with the same receptors in bovine endometrium.
Journal of Biological Chemistry 269 (18), 13 544-13 550.
Lyseng-Williamson, K. and Plosker, G. 2002. Management of relapsing-remitting multiple sclerosis - defi ning
the role of subcutaneous recombinant interferon-β-1a (Rebif). Disease Management and Health Outcomes
10 (5), 307-325.
Meager, A. 2002. Biological assays for interferons. Journal of Immunological Methods 261 (1-2), 21-36.
Pestka, S. and Langer, J. 1987. Interferons and their actions. Annual Review of Biochemistry 56 , 727-777.
Platanias, L. 2005. Mechanisms of type-I and type-II interferon-mediated signalling. Nature Reviews Immunol-
ogy 5 (5), 375-386.